**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 52189

**Manuscript Type:** CASE REPORT

**Radiation recall dermatitis with dabrafenib and trametinib: A case report**

Yilmaz M *et al*. Radiation dermatitis with dabrafenib plus trametinib

Mesut Yilmaz, Ugur Celik, Seyhan Hascicek

**Mesut Yilmaz,** Medical Oncology Department, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34144, Turkey

**Ugur** **Celik,** Dermatology Department, Medipol Kosuyolu Hospital, Istanbul 34134, Turkey

**Seyhan** **Hascicek,** Pathology Department, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul 34134, Turkey

**Author contributions:** Yilmaz M and Celik U contributed equally to this work; Yilmaz M designed the case report; Hascicek S carried out pathological evaluations; Yilmaz M wrote the paper.

**Corresponding author: Mesut Yilmaz,** **MD, Doctor,** Medical Oncology Department, Bakırköy Sadi Konuk Training and Research Hospital, Istanbul 34144, Turkey. mesutyilmaz12@yahoo.com

**Received:** October 20, 2019

**Revised:** December 9, 2019

**Accepted:** December 14, 2019

**Published online:**

**Abstract**

BACKGROUND

Radiation recall dermatitis has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been documented.

CASE SUMMARY

Here, we report the rare occurrence of radiation recall dermatitis after palliative radiotherapy for bone metastases in a metastatic melanoma patient treated with a combination of dabrafenib and trametinib.

CONCLUSION

We present a case of radiation recall dermatitis after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib. This is a very rare toxic event, and there is insufficient data to describe prevention strategies. Increased awareness and reporting of cases will help to better explain the association between targeted therapy and the radiation recall phenomenon.

**Key words:**Radiation recall dermatitis; Melanoma; Radiotherapy; Dabrafenib; Trametinib; Case report

Yilmaz M, Celik U, Hascicek S.Radiation recall dermatitis with dabrafenib and trametinib: A case report. *World J Clin Cases* 2019; In press

**Core tip:** Radiation recall dermatitis is a very rare toxic event. Here we report a case of this phenomenon after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib.

**INTRODUCTION**

Radiation recall dermatitis is an acute inflammatory reaction confined to previously irradiated skin, which occurs after the administration of certain drugs, mainly cytotoxic chemotherapeutics such as anthracyclines (doxorubicin), taxanes (paclitaxel), and antimetabolites (gemcitabine, capecitabine), but other triggers include several antibiotics, antituberculosis drugs, and simvastatin[1,2]. The reaction can present days or even years after radiotherapy[1,2].

Dabrafenib is a potent, ATP-competitive inhibitor of RAF kinases, including BRAF, which is highly active in melanoma, both as monotherapy and in combination with MEK inhibitors. Dabrafenib plus trametinib is a standard treatment option for advanced BRAF V600 mutated melanoma[3]. We report a case of radiation recall dermatitis occurring 30 d after completion of palliative radiotherapy while the patient was treated with a combination of dabrafenib and trametinib.

**CASE PRESENTATION**

***Chief complaints***

Discolored and inflamed skin.

***History of present illness***

One month after completion of radiotherapy, a 76-year-old man was admitted to the oncology clinic due to discolored and inflamed skin limited to the region that was previously irradiated while still taking BRAF and MEK inhibitor combination therapy (Figure 1). Two weeks later, a similar lesion was seen in the left lower extremity (Figure 2).

***History of past illness***

The patient who was previously healthy was admitted to the hospital with an ulcerated lesion located in the right parietal region of the scalp in July 2015. After excision of the lesion, a pT4bN0M0 nodular melanoma was detected. He was started on adjuvant interferon therapy but this was discontinued due to grade 3 hepatotoxicity and fatigue. Bone and subcutaneous metastases were detected in August 2017 and BRAF V600E mutation was positive. Dabrafenib and trametinib were prescribed, and subcutaneous metastases regressed with this treatment, while bone metastases were stable. In January 2019, he complained of right lower leg pain and palliative radiotherapy, 20 gray in 5 fractions, was applied to bone metastasis in the right tibia region.

***Personal and family history***

He was treated for stage four melanoma with dabrafenib plus trametinib. He did not receive any other medications except dabrafenib and trametinib.

***Physical examination upon admission***

One month after completion of radiotherapy, the patient detected discolored and inflamed skin limited to the region previously irradiated, while he was still receiving BRAF and MEK inhibitor combination therapy (Figure 1). He did not take any other medications except dabrafenib and trametinib.

***Laboratory examinations***

Laboratory tests such as normal C-reactive protein levels and complete blood count without leucocytosis ruled out infection.

***Imaging examinations***

A dermal biopsy was performed and orthokeratotic epidermis with lymphocytic infiltration was observed in the pathologic specimen, with no sign of malignancy (Figure 3).

**FINAL DIAGNOSIS**

Radiation recall dermatitis.

**TREATMENT**

He was treated with topical steroids, nonsteroidal anti-inflammatory agents, and antihistamines. Two weeks after this intervention all skin lesions had disappeared.

**OUTCOME AND FOLLOW-UP**

Two weeks after topical therapy all skin lesions had disappeared. He is still receiving BRAF-MEK inhibitor combination therapy and continues to benefit from this treatment.

**DISCUSSION**

Radiation recall phenomenon was firstly described by D’Angio *et al*[4] in 1959, but the pathophysiology of radiation recall dermatitis is still not well understood. Clinical diagnosis is based on patient history, symptoms, physical exam findings, and the exclusion of other causes of dermatitis. Vascular damage, epithelial stem cell depletion, epithelial stem cell sensitization, and an idiosyncratic drug hypersensitivity reaction have been proposed as potential mechanisms of this phenomenon[1,5,6]. It is mostly seen after the administration of standard cytotoxic chemotherapy agents, and the incidence of radiation recall with targeted therapies is not well known[1,2]. Here we report a patient treated with dabrafenib and trametinib who was diagnosed with radiation recall dermatitis after palliative radiation to bone metastasis.

An institutional review of targeted therapy–induced radiation recall by Levy *et al*[7] described 16 cases associated with various agents, including mechanistic target of rapamycin inhibitors (everolimus, temsirolimus), epidermal growth factor receptor inhibitors (cetuximab), histone deacetylase inhibitors, and BRAF inhibitors (vemurafenib)[7]. Dabrafenib is a BRAF inhibitor indicated for advanced melanoma and non-small cell lung cancer patients harboring the BRAF mutation. It is used with trametinib which is a MEK inhibitor[8].

Vemurafenib was the first BRAF inhibitor to be used, and in the literature, several cases of radiation recall phenomenon due to vemurafenib have been reported. Haraldsdottir *el al*[9] also reported radiation recall dermatitis with concomitant dabrafenib and pazopanib therapy. Their patient was treated for BRAF mutated, metastatic, non–small-cell lung adenocarcinoma of the bone and thoracic lymph nodes, and received whole-femur irradiation. Similarly, our patient was treated with tyrosine kinase inhibitors, dabrafenib and trametinib, his tibia was irradiated due to metastatic disease and he subsequently developed radiation recall dermatitis.

In previous reports, patients were diagnosed with targeted therapy-induced radiation recall dermatitis based on the following clinical findings: acute inflammatory skin reaction with localized symptoms such as painless erythematous lesion, dry desquamation, pruritus, and patchy hyperpigmentation within a previously irradiated area, skin reaction development during targeted therapy, no other suspected medication, and negative test results for local skin infection[6,8-10]. The patient in our study also experienced localized acute inflammatory symptoms in the irradiated area without evidence of infection during dabrafenib and trametinib treatment. He did not take any other medications except dabrafenib and trametinib before the development of radiation recall dermatitis and there were no signs of skin infection.

Histological findings of sorafenib-induced radiation recall dermatitis were reported in a patient. Skin biopsy of an erythematous lesion revealed a diffuse perivascular lymphohistiocytic infiltrate with few eosinophils in the corium, and apoptotic keratinocytes and distinct vacuolization in the junction zone[11]. Our patient’s skin biopsy revealed orthokeratotic epidermis with lymphocytic infiltration.

The management of radiation recall dermatitis has included oral or topical steroids, nonsteroidal anti-inflammatory drugs, and antihistamines. It is not clear whether these agents hasten the recovery[1]. Many reports suggest discontinuing treatment with the offending agent; however, Conen *et al*[12] reported a patient who successfully continued vemurafenib therapy despite the occurrence of radiation recall. Similarly, we decided to continue the treatment of metastatic melanoma with dabrafenib and trametinib, and the patient still benefits from this combination therapy.

**CONCLUSION**

Here we present a case of radiation recall dermatitis after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib. This is a very rare toxic event, and there is insufficient data to describe prevention strategies. Increased awareness and reporting of cases will help to better explain the association between targeted therapy and the radiation recall phenomenon.

**References**

1 **Camidge R**, Price A. Characterizing the phenomenon of radiation recall dermatitis. *Radiother Oncol* 2001; **59**: 237-245 [PMID: 11369064 DOI: 10.1016/s0167-8140(01)00328-0]

2 **Azria D**, Magné N, Zouhair A, Castadot P, Culine S, Ychou M, Stupp R, Van Houtte P, Dubois JB, Ozsahin M. Radiation recall: a well recognized but neglected phenomenon. *Cancer Treat Rev* 2005; **31**: 555-570 [PMID: 16168567 DOI: 10.1016/j.ctrv.2005.07.008]

3 **Flaherty KT**, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* 2012; **367**: 1694-1703 [PMID: 23020132 DOI: 10.1056/NEJMoa1210093]

4 **D'ANGIO GJ**, FARBER S, MADDOCK CL. Potentiation of x-ray effects by actinomycin D. *Radiology* 1959; **73**: 175-177 [PMID: 13813586 DOI: 10.1148/73.2.175]

5 **Seymour CB**, Mothersill C, Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. *Int J Radiat Biol Relat Stud Phys Chem Med* 1986; **50**: 167-179 [PMID: 3487520 DOI: 10.1080/09553008614550541]

6 **Boström A**, Sjölin-Forsberg G, Wilking N, Bergh J. Radiation recall--another call with tamoxifen. *Acta Oncol* 1999; **38**: 955-959 [PMID: 10606426 DOI: 10.1080/028418699432653]

7 **Levy A**, Hollebecque A, Bourgier C, Loriot Y, Guigay J, Robert C, Delaloge S, Bahleda R, Massard C, Soria JC, Deutsch E. Targeted therapy-induced radiation recall. *Eur J Cancer* 2013; **49**: 1662-1668 [PMID: 23312391 DOI: 10.1016/j.ejca.2012.12.009]

8 **Long GV**, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* 2015; **386**: 444-451 [PMID: 26037941 DOI: 10.1016/S0140-6736(15)60898-4]

9 **Haraldsdottir S**, Bertino E, Haglund K, Kaffenberger B, Shah MH. Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy. *JAMA Dermatol* 2016; **152**: 587-589 [PMID: 26886900 DOI: 10.1001/jamadermatol.2015.5366]

10 **Chung C**, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. *Anticancer Drugs* 2010; **21**: 206-209 [PMID: 19952730 DOI: 10.1097/CAD.0b013e328333d679]

11 **Stieb S**, Riesterer O, Brüssow C, Pestalozzi B, Guckenberger M, Weiler S. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature. *Strahlenther Onkol* 2016; **192**: 342-348 [PMID: 26907093 DOI: 10.1007/s00066-016-0950-7]

12 **Conen K**, Mosna-Firlejczyk K, Rochlitz C, Wicki A, Itin P, Arnold AW, Gross M, Zimmermann F, Zippelius A. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. *Dermatology* 2015; **230**: 1-4 [ PMID: 25472806 DOI: 10.1159/000365918]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2013), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** October 20, 2019

**First decision:** November 13, 2019

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** Turkey

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Lin Q **S-Editor:** Zhang L **L-Editor:** Webster JR **E-Editor:**


**Figure Legends**



**Figure 1 One month after completion of radiotherapy, discolored and inflamed skin limited to the region previously irradiated was observed while being treated with BRAF and MEK inhibitor combination therapy.** A: Front view of right leg-discolored and inflamed skin limited to the region previously irradiated; B: Back view of right leg-discolored and inflamed skin limited to the region previously irradiated; C: Front view of right leg; D: Back view of right leg.



**Figure 2 Similar lesions on the opposite leg.**

****

**Fıgure 3** A **dermal biopsy was performed and orthokeratotic epidermis with lymphocytic infiltration was observed in the pathologic specimen.** A: Perivascular lymphocytes (Hematoxylin-eosin staining, × 20); B: Perivascular lymphocytes (Hematoxylin-eosin staining, × 20).